Generic Ozempic Is Here. Will Your Drug Plan Actually Save Money?

If drug costs have been climbing on your group benefits plan, GLP-1 medications like Ozempic are likely part of the reason. These drugs have been among the fastest-growing cost drivers in employer-sponsored plans across the country. So when Health Canada approved a generic version of semaglutide, the active ingredient in Ozempic, on April 28, 2026, and a second generic followed in early May, it was welcome news for anyone managing a group drug plan. Canada was the first G7 country to approve a generic semaglutide.

But here is the thing: lower costs are not guaranteed just because a cheaper version of the drug exists. Whether your plan actually sees savings depends almost entirely on how it is designed.

What Happens When a Drug Goes Generic?

When a brand-name drug loses patent protection, other manufacturers can produce and sell equivalent versions at a lower cost. The savings can be significant.

As a rule of thumb in the industry, when one or two generics enter the market, prices may fall by 20 to 30 per cent below the brand-name drug. With more generics competing over time, those discounts can deepen further. These are general industry estimates, and actual outcomes will vary.

For Ozempic specifically, this could translate to roughly one to two per cent savings on a plan's total drug costs. That may sound modest, but for organizations with meaningful Ozempic spend, it adds up quickly, especially at renewal.

Why Savings Do Not Happen Automatically

Here is where many plan sponsors get caught off guard: the existence of a generic does not mean your plan will automatically pay for it at the lower price.

Without specific plan design provisions in place, many members may stay on the brand-name drug. Their doctor prescribed it. They have been taking it. They may not even know a generic exists. And if your plan covers it without any substitution requirement, there is little reason to switch.

The result is a plan that may continue paying brand-name prices for a drug that now has a lower-cost equivalent on the market.

What Plan Sponsors Can Do Right Now

The arrival of generic Ozempic creates a real window to act, but it requires a conversation with us. Here are the three areas worth reviewing:

Generic substitution policies. Many plans already have mandatory substitution clauses that require members to use a generic when one is available, unless there is a medical reason not to. If your plan does not have this in place, or if it only applies to certain drug categories, now is the time to review it. Adding generic substitution for GLP-1 medications could meaningfully reduce what the plan pays.

Prior authorization requirements. Prior authorization means a member needs approval before the plan will cover a specific drug. This is particularly useful for high-cost medications where clinical criteria should be confirmed before coverage is granted. It also creates a natural point to direct members to the generic option. If your plan does not currently require prior authorization for GLP-1 medications, that is worth exploring with your insurer.

Brand-name pricing negotiations. In some cases, insurers may be able to negotiate pricing directly with brand-name drug manufacturers. This is not a standard plan-design feature, but it is worth asking your insurer whether it is an option and whether brand-name semaglutide pricing is available through their arrangements. If it is available, it could help reduce costs even for members who remain on the brand-name drug for medical reasons.

The Bigger Picture on Plan Design

Generic Ozempic is a useful reminder that drug plan management is not a set-it-and-forget-it exercise. Small design decisions, like whether a plan has a substitution clause or a prior authorization requirement for high-cost drugs, can translate into real, measurable differences in cost over time.

For organizations that have seen drug costs climb in recent years, this is a meaningful opportunity. The savings potential is real. Whether your plan captures it depends on reviewing your plan design and having a conversation with us before your next renewal.

This content is provided for general informational purposes only. It is not intended to provide investment, tax, or legal advice, and should not be relied upon as such. 

Sources:

•  Generic Ozempic could trim employer drug costs, but savings depend on plan design: expert - Benefits Canada
•  Canada becomes the first G7 country to approve a generic version of semaglutide - Health Canada
•  Drug plan management and generic substitution - Canadian Life and Health Insurance Association